AstraZeneca initiates phase III immunotherapy study for MEDI4736 in patients with lung cancer
First MedImmune oncology immunotherapy targeting the PD-L1/PD-1 pathway progresses into Phase IIIAstraZeneca today announced the start of the Phase III programme for MEDI4736, an immunotherapy in development for the treatment of non-small cell lung cancer (NSCLC) and other cancers. The goal of the PACIFIC trial, the first study in the Phase III NSCLC programme, is to evaluate progression free survival and overall survival of MEDI4736 compared to placebo in patients with locally advanced, unresectable NSCLC (Stage III) following completion of treatment with chemoradiotherapy and no evidence